EPIX MEDICAL INC
10-Q, EX-27.1, 2000-11-13
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: EPIX MEDICAL INC, 10-Q, 2000-11-13
Next: ALLEN & CO INC, 13F-HR, 2000-11-13



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET OF EPIX MEDICAL, INC. AS OF SEPTEMBER 30, 2000 AND FOR THE NINE MONTH
PERIOD ENDED SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                       3,965,206
<SECURITIES>                                25,308,773
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            30,356,815
<PP&E>                                       4,487,374
<DEPRECIATION>                             (3,133,448)
<TOTAL-ASSETS>                              31,845,601
<CURRENT-LIABILITIES>                       10,478,660
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       131,145
<OTHER-SE>                                  18,284,478
<TOTAL-LIABILITY-AND-EQUITY>                31,845,601
<SALES>                                              0
<TOTAL-REVENUES>                             4,781,957
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                            19,566,017
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             344,019
<INCOME-PRETAX>                           (14,310,762)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                       (14,310,762)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (14,310,762)
<EPS-BASIC>                                     (1.17)
<EPS-DILUTED>                                   (1.17)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission